Regen BioPharma Inc. (OTCQB: RGBP), (OTCQB: RGBPP) announced today the filing of a [provisional/nonprovisional] utility patent application with the United States Patents and Trademark Office covering NR2F6-silenced CAR T cells. While previous work demonstrated that methodologies developed by Regen and covered under its issued patent #9,091,696 are useful in stimulation of T cell activity, the current patent further modifies T cells to express molecules that act as a localized “danger signal” to the immune system. CAR T cells are T Cells (T lymphocytes ) which are genetically engineered to produce chimeric antigen receptors (CARs) on their surface. CARs are proteins that allow the T cells to recognize an antigen on targeted tumor cells.

Leave a Reply

Your email address will not be published.